U.S. markets closed
  • S&P Futures

    4,164.75
    +4.75 (+0.11%)
     
  • Dow Futures

    34,157.00
    +39.00 (+0.11%)
     
  • Nasdaq Futures

    13,517.50
    +26.50 (+0.20%)
     
  • Russell 2000 Futures

    2,240.90
    +4.30 (+0.19%)
     
  • Crude Oil

    65.41
    -0.22 (-0.34%)
     
  • Gold

    1,785.20
    +0.90 (+0.05%)
     
  • Silver

    26.41
    -0.11 (-0.42%)
     
  • EUR/USD

    1.2012
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.5840
    -0.0080 (-0.50%)
     
  • Vix

    19.15
    -0.33 (-1.69%)
     
  • GBP/USD

    1.3910
    +0.0003 (+0.02%)
     
  • USD/JPY

    109.3340
    +0.1450 (+0.13%)
     
  • BTC-USD

    56,872.73
    +2,005.00 (+3.65%)
     
  • CMC Crypto 200

    1,457.27
    +51.97 (+3.70%)
     
  • FTSE 100

    7,039.30
    +116.13 (+1.68%)
     
  • Nikkei 225

    29,314.74
    +502.11 (+1.74%)
     

PTC Therapeutics-Roche's Evrysdi Approved In Europe For Muscular Atrophy

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • The European Commission (EC) has granted marketing authorization to PTC Therapeutics Inc's (NASDAQ: PTCT) Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in patients two months and older.

  • Evrysdi will be for SMA Type 1, Type 2, or Type 3 patients with one to four SMN2 copies.

  • The EC approval is based on two studies - Efficacy results from the FIREFISH study in infants aged 2 to 7 months with symptomatic Type 1 SMA and the SUNFISH study in children and young adults with Type 2 or 3 SMA.

  • Evrysdi is commercialized in the U.S. by Genentech, a Roche Holdings AG member (OTCMKTS: RHHBY).

  • Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics.

  • Price Action: PTCT shares closed 2.3% lower at $48.06 on Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.